Search Results

Data from the first US comprehensive single center experience at St Bernard’s Medical Center and Arrhythmia Research Group, presented at a Late-Breaking session at the AF Symposium 2024 in Boston, shows that Left Atrial Appendage Occlusion (LAAO) procedures planned by means of FEops HEARTguideTM result in significantly improved procedural efficiency.

FEops announced today its new release of FEops HEARTguide™, including an AI-based anatomical analysis of MSCT images for the pre-operative planning of structural heart interventions.

FEops announces Euan S. Thomson, PhD has been appointed as new Chairman.

FEops announced that it received authorization from the U.S. Food and Drug Administration for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion with the Abbott’s Amplatzer™ Amulet™ and Boston Scientific’s Watchman FLX™ device*.

Data from the PRECISE-TAVI study, presented at the PCR Valves 2022 convention in London shows that Transcatheter Aortic Valve Implantation (TAVI) procedures planned by means of FEops HEARTguideTM result in an important change of pre-procedural decision making of the heart team, associated with favorable clinical outcomes.

FEops today announced that it received De Novo authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion with the Boston Scientific WATCHMAN™ device*.

FEops, a digital health leader in personalized predictive planning for structural heart interventions, is proud to announce having modeled 2000 patients with FEops HEARTguide™ for the pre-operative planning of structural heart interventions.

FEops, a leader in predictive planning for structural heart interventions, is proud to announce that its simulation technology supported TRiCares from initial design concept to a successful first-in-human of the Topaz Tricuspid Valve Replacement (TTVR) system, developed by TRiCares SAS.

FEops, a leader in personalized predictive planning for structural heart interventions, is proud to announce that FEops HEARTguideTM was the winning entry at CSI Frankfurt 2019 voted on by physician attendees for the Highlight of the year award in the category interventional imaging

FEops, a leader in personalized predictive planning for structural heart interventions, today announced that FEops HEARTguideTM has received CE mark approval. FEops HEARTguideTM is a one-in-its-kind procedure planning environment for structural heart interventions that provides physicians unique insights to evaluate device sizing and positioning pre-operatively using novel computational modeling and simulation technology.